Masitinib Emerging Drug Insight and Market Forecast - 2032

“Masitinib Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about masitinib for Amyotrophic Lateral Sclerosis in seven major markets. A detailed picture of the masitinib for Amyotrophic Lateral Sclerosis in 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 -2032 is provided in this report along with a detailed description of the masitinib for Amyotrophic Lateral Sclerosis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the masitinib market forecast analysis for Amyotrophic Lateral Sclerosis in 7MM, SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Amyotrophic Lateral Sclerosis.

Drug Summary

Masitinib (AB1010) is an orally administered tyrosine kinase inhibitor. It modulates mast cells and macrophages' activity - important cells for immunity - by targeting a limited number of kinases without inhibiting, at therapeutic doses, kinases associated with known toxicities.

Based on its unique mechanism of action, masitinib can be developed in many conditions in oncology, inflammatory diseases, and certain diseases of the central nervous system. In oncology, masitinib has the potential to improve survival when administered alone or in combination with chemotherapy via targeting of specific gene mutations or because of its immunotherapeutic properties. Masitinib can exert a neuroprotective effect in some central nervous system diseases and reduce symptoms in some chronic inflammatory disorders through its activity on mast cells and microglia, with subsequent modulation of inflammatory and neurodegenerative processes.

AB Science has already completed a Phase II/III trial and has attained positive results from it, followed by a green signal from the US FDA on the IND application. However, the drug is under investigation for a phase III trial in patients with Amyotrophic Lateral Sclerosis. The FDA and EMA have granted Orphan Indication to masitinib for the treatment of Amyotrophic Lateral Sclerosis.

The Phase III trial was put on hold due to a potential risk of ischemic heart disease with masitinib voluntary by the company, but the trial has now resumed after the FDA authorization.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the masitinib description, mechanism of action, dosage and administration, research and development activities in Amyotrophic Lateral Sclerosis.
• Elaborated details on masitinib regulatory milestones and other development activities have been provided in this report.
• The report also highlights the masitinib research and development activities in Amyotrophic Lateral Sclerosis across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around masitinib.
• The report contains forecasted sales of masitinib for Amyotrophic lateral sclerosis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Amyotrophic Lateral Sclerosis.
• The report also features the SWOT analysis with analyst views for masitinib in Amyotrophic Lateral Sclerosis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Masitinib Analytical Perspective

In-depth Masitinib Market Assessment

This report provides a detailed market assessment of masitinib for amyotrophic lateral sclerosis in seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

Masitinib Clinical Assessment

The report provides the clinical trials information of masitinib for Amyotrophic Lateral Sclerosis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Amyotrophic lateral sclerosis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence masitinib dominance.
• Other emerging products for Amyotrophic Lateral Sclerosis are expected to give tough market competition to masitinib and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of masitinib in Amyotrophic Lateral Sclerosis.
• Our in-depth analysis of the forecasted sales data of masitinib from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the masitinib in Amyotrophic Lateral Sclerosis.

 

Key Questions Answered

• What is the product type, route of administration and mechanism of action of masitinib?
• What is the clinical trial status of the study related to masitinib in amyotrophic lateral sclerosis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the masitinib development?
• What are the key designations that have been granted to masitinib for Amyotrophic Lateral Sclerosis?
• What is the forecasted market scenario of masitinib for Amyotrophic Lateral Sclerosis?
• What are the forecasted sales of masitinib in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to masitinib for Amyotrophic Lateral Sclerosis?
• Which are the late-stage emerging therapies under development for the treatment of Amyotrophic Lateral Sclerosis?